This is a news story, published by EurekAlert!, that relates primarily to the Heart Failure Society of America Annual Scientific Meeting news.
For more disease research news, you can click here:
more disease research newsFor more news from EurekAlert!, you can click here:
more news from EurekAlert!Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like disease research news, you might also like this article about
nonsteroidal mineralocorticoid receptor antagonist finerenone. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest Heart Failure Society news, clinical trial news, disease research news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
heart failureEurekAlert!
•87% Informative
Long-term treatment with the nonsteroidal mineralocorticoid receptor antagonist finerenone was estimated to extend event-free survival by up to 3 years among people with heart failure with mildly reduced or preserved ejection fraction.
The study is being presented at the Heart Failure Society of America Annual Scientific Meeting .
VR Score
91
Informative language
93
Neutral language
61
Article tone
formal
Language
English
Language complexity
83
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
long-living
External references
2
Source diversity
2
Affiliate links
no affiliate links